Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Enhanced activity of hu14.18-il2 immunocytokine against murine nxs2 neuroblastoma when combined with interleukin 2 therapy

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Neal, Z. C.
  • Yang, J. C.
  • Rakhmilevich, A. L.
  • Buhtoiarov, I. N.
  • Lum, H. E.
  • Imboden, M.
  • Hank, J. A.
  • Lode, H. N.
  • Reisfeld, Ralph
  • Gillies, S. D.
  • Sondel, P. M.

publication date

  • 2004

journal

  • Clinical Cancer Research  Journal

abstract

  • Established s.c. NXS2 murine neuroblastoma tumors exhibited transient resolution after suboptimal therapy using the hu14.18-IL2 immunocytokine (IC). The hu14.18-IL2 IC is a fusion protein that has linked a molecule of interleukin 2 (IL-2) to the COOH terminus of each of the IgG heavy chains on the humanized anti-GD(2) monoclonal antibody hu14.18. To induce more potent and longer lasting in vivo antitumor effects, we tested hu14.18-IL2 IC in a regimen combining it with constant infusion IL-2 in NXS2 tumor-bearing mice. The addition of the constant infusion IL-2 augmented the antitumor response induced by treatment with the hu14.18-IL2 IC in animals with experimentally induced hepatic metastases and in animals bearing localized s.c. tumors. The combined treatment induced prolonged tumor eradication in most animals bearing s.c. tumors and involved both natural killer cells and T cells. The enhanced ability of this combined treatment to prevent tumor recurrence was not observed when a larger dose of hu14.18-IL2 IC, similar in IL-2 content to the IC plus systemic IL-2 regimen, was tested as single-agent therapy. Animals showing prolonged tumor eradication of established tumors after the combined hu14.18-IL2 plus IL-2 regimen exhibited a protective T-cell-dependent antitumor memory response against NXS2 rechallenge.

subject areas

  • Animals
  • Antibodies, Monoclonal
  • Cell Line, Tumor
  • Cytotoxicity, Immunologic
  • Female
  • Gangliosides
  • Humans
  • Interleukin-2
  • Killer Cells, Natural
  • Liver Neoplasms, Experimental
  • Mice
  • Mice, Inbred Strains
  • Neoplasm Metastasis
  • Neuroblastoma
  • Recombinant Fusion Proteins
  • Spleen
  • Time Factors
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 1078-0432

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.ccr-03-0799

PubMed ID

  • 15269160
scroll to property group menus

Additional Document Info

start page

  • 4839

end page

  • 4847

volume

  • 10

issue

  • 14

©2019 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support